Core Viewpoint - Shenzhen Kangtai Biological Products Co., Ltd. has achieved significant recognition in the field of vaccine research and development, particularly through its subsidiary Beijing Minhui Biological Technology Co., Ltd., which recently won the second prize of the Jiangsu Provincial Science and Technology Progress Award for its project on rapid confirmation and precise prevention of emerging viral infectious diseases [1][2]. Group 1: Project Recognition - The project "Key Technology Innovation and Application for Rapid Confirmation and Precise Prevention of Emerging Viral Infectious Diseases" addresses critical challenges in the prevention and control of new viral infectious diseases [1]. - The project was led by the Jiangsu Provincial Center for Disease Control and Prevention and nominated by the Provincial Health Commission, highlighting the importance of collaboration in public health initiatives [1]. Group 2: Vaccine Development - Minhui Biological's independently developed inactivated virus vaccine platform is a core component of the project, receiving high recognition for its innovation, practicality, and scientific value [2]. - The company has successfully obtained clinical trial approval from the National Medical Products Administration for its bivalent and quadrivalent inactivated enterovirus vaccines, with the quadrivalent vaccine currently in Phase I clinical trials [2]. - There are currently no approved bivalent or quadrivalent enterovirus vaccines available globally, indicating a significant market opportunity for the company [2]. Group 3: Strategic Implications - The recent award is seen as a validation of the company's commitment to independent innovation and its comprehensive strength in vaccine research and development, which is expected to enhance its core competitiveness and influence in the market [2]. - Successful development of these vaccines could further enrich the company's multi-valent vaccine portfolio, solidifying its market position and providing a strong foundation for sustainable growth [2].

Core Viewpoint - The company focuses on high-tech film sectors, emphasizing innovation in process technology and new product development [1] Group 1: Business Focus - The company is dedicated to the development of functional polyester films and optical films as its two main business areas [1] - The company employs a comprehensive control model encompassing "R&D + procurement + production + sales" to accurately meet market demands [1]

证券日报网讯 2月9日，航天彩虹在互动平台回答投资者提问时表示，公司始终秉持服务国家战略与参 与国际合作的宗旨，彩虹-7的研发与市场规划严格遵循国家相关政策和指导方向。公司坚持以市场需求 为导向，产品具备服务国内国际两个市场的潜力，将根据国家有关规定以及不同市场客户的需求，依法 依规、灵活有序地开展相关业务，并为投资者创造可持续价值。 （编辑 王雪儿） ...

Core Viewpoint - The company, 聚光科技, is making significant progress in the development of a high-resolution static ion trap Fourier transform mass spectrometer, which is a key national research project led by its subsidiary, 谱育科技 [1] Group 1: Project Development - The project has successfully completed the integration and testing of the prototype [1] - A mid-term review of the project has been completed, indicating that key technological developments are on track [1] Group 2: Product Impact - The development and industrialization of high-resolution static trap mass spectrometry products will enhance the company's high-end mass spectrometry product lineup [1] - This advancement is expected to accelerate the domestic substitution of products in high-level scientific research fields [1]

（编辑 王雪儿） 证券日报网讯 2月9日，沪电股份在互动平台回答投资者提问时表示，公司在多年的发展历程中，一贯 注重工艺改进与技术创新，及时把握细分领域高端产品需求，持续保持自身研发水平的领先性和研究方 向的前瞻性。 ...

（编辑 楚丽君） 证券日报网讯 2月9日，齐峰新材在互动平台回答投资者提问时表示，全球乳胶纸市场容量约为9万吨， 其中高端乳胶纸市场容量约4万吨，中低档乳胶纸市场容量约5万吨，全球主要公司是齐峰新材、美国尼 纳和法国明士克。目前公司是国内唯一一家可以稳定批量提供高、中档乳胶纸的生产厂家。公司目前有 40多个成熟乳胶纸品种，在手订单充足。 ...

证券日报网讯 2月9日，迈赫股份在互动平台回答投资者提问时表示，公司目前在手订单充足，依据深 圳证券交易所相关规定，公司已预约于2026年4月29日披露2025年年度报告，在手订单情况将在公司 2025年年度报告中披露。公司2026年的生产工作正按照既定计划稳步推进，各项生产环节运转良好。 （编辑 王雪儿） ...

Core Viewpoint - Tongce Medical announced a change in the quality control reviewer for its 2025 audit services, appointing Xu Juping to replace Wang Qichao due to internal adjustments at Zhonghui [1] Group 1 - The company has appointed Xu Juping as the quality control reviewer for the 2025 audit services [1] - The previous reviewer, Wang Qichao, has been replaced due to internal work adjustments at Zhonghui [1]

Core Viewpoint - The company is expanding its presence in the power semiconductor sector through the acquisition of its subsidiary, Jilaiwei, which focuses on integrated design and manufacturing of semiconductor chips and devices [1] Group 1: Company Overview - Jilaiwei is a vertically integrated (IDM) enterprise specializing in power semiconductor chips and devices, encompassing chip design, wafer manufacturing, and packaging testing [1] - The products of Jilaiwei are applied in various fields including consumer electronics, industrial control, communication security, automotive electronics, and military applications [1] Group 2: Strategic Developments - The company completed a significant asset purchase of Jilaiwei in September 2025, marking its entry into the research, production, and sales of power semiconductor chips and devices [1] - This acquisition optimizes and extends the company's industrial chain layout, accelerating its positioning and breakthroughs in the high value-added, high-tech integrated circuit core sector [1] Group 3: Financial Integration - Jilaiwei's revenue will be included in the company's consolidated financial statements starting from the fourth quarter of 2025, with full-year revenue integration commencing in 2026 [1]

（编辑 王雪儿） 证券日报网讯 2月9日，国药现代在互动平台回答投资者提问时表示，医药研发具有周期长、投入大、 风险高的特性，公司将坚持"创新驱动"发展战略，深化合作创新，努力推动创新突破。如有重大事项公 司将及时履行信息披露义务。请以公司后续公告及定期报告披露信息为准。 ...